SCHEMBL24968351

SCHEMBL24968351

Cc1cc(C(F)(F)F)cnc1N1CCN(C(=O)OCCc2c[nH]c(=O)c(C(F)(F)F)c2)CC1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
SMN1; SMN2 Q16637 3/20 0.45
HPGD P15428 2/20 0.45
SLC6A9 P48067 1/20 0.40
SLC6A5 Q9Y345 1/20 0.40
TIPARP Q7Z3E1 5/20 0.40
ALDH1A1 P00352 4/20 0.39
MAPT P10636 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39
RBP4 P02753 1/20 0.38
RECQL P46063 1/20 0.38
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24967960 0.91 MEN1 (0.49) MEN1KMT2ASMN1; SMN2HPGDSLC6A9
SCHEMBL24968233 0.90 KMT2A (0.48) MEN1KMT2ASMN1; SMN2HPGDTIPARP
SCHEMBL27233858 0.88 MEN1 (0.46) MEN1KMT2ASMN1; SMN2HPGDSLC6A9
SCHEMBL24968229 0.87 TIPARP (0.52) MEN1KMT2ASMN1; SMN2HPGDTIPARP
SCHEMBL24968471 0.85 SMN1; SMN2 (0.60) MEN1KMT2ASMN1; SMN2HPGDALDH1A1
SCHEMBL24967941 0.85 TIPARP (0.43) MEN1KMT2ASMN1; SMN2HPGDTIPARP
SCHEMBL24967947 0.84 TIPARP (0.46) MEN1KMT2ASMN1; SMN2HPGDTIPARP
SCHEMBL24967958 0.81 HPGD (0.42) MEN1KMT2ASMN1; SMN2HPGDSLC6A9
SCHEMBL24968925 0.80 TIPARP (0.40) MEN1KMT2ASMN1; SMN2HPGDTIPARP
SCHEMBL24968211 0.80 TIPARP (0.40) MEN1KMT2ASMN1; SMN2HPGDTIPARP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240351997-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) 2024-10-24 US disclosed
EP-4378938-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2024-06-05 EP disclosed
WO-2023006013-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2023-02-02 WO disclosed
WO-2023006013-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240351997-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF PARP6, PARP4, PARP3 MEN1 2207/4885KMT2A 1024/4885SMN1; SMN2 3311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.